Institutional shares held 108 Million
8K calls
3K puts
Total value of holdings $102M
$7K calls
$2K puts
Market Cap $161M
169,755,008 Shares Out.
Institutional ownership 63.45%
# of Institutions 139


Latest Institutional Activity in LCTX

Top Purchases

Q2 2025
Kapitalo Investimentos Ltda Shares Held: 27.1K ($25.8K)
Q2 2025
Sound Income Strategies, LLC Shares Held: 4 ($3.8)
Q1 2025
Broadwood Capital Inc Shares Held: 49.6M ($47.1M)
Q1 2025
Comerica Bank Shares Held: 3M ($2.85M)
Q1 2025
Geode Capital Management, LLC Shares Held: 4.49M ($4.26M)

Top Sells

Q2 2025
Org Partners LLC Shares Held: 59.2K ($56.2K)
Q2 2025
Gsa Capital Partners LLP Shares Held: 898K ($853K)
Q2 2025
Farther Finance Advisors, LLC Shares Held: 84 ($79.8)
Q1 2025
Mai Capital Management Shares Held: 64.4K ($61.2K)
Q1 2025
Jpmorgan Chase & CO Shares Held: 605K ($575K)

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.


Insider Transactions at LCTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
8.05M Shares
From 7 Insiders
Open market or private purchase 8.02M shares
Exercise of conversion of derivative security 37.3K shares
Sell / Disposition
15K Shares
From 2 Insiders
Payment of exercise price or tax liability 15K shares

Track Institutional and Insider Activities on LCTX

Follow Lineage Cell Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LCTX shares.

Notify only if

Insider Trading

Get notified when an Lineage Cell Therapeutics, Inc. insider buys or sells LCTX shares.

Notify only if

News

Receive news related to Lineage Cell Therapeutics, Inc.

Track Activities on LCTX